PerkinElmer Provides Solutions for Collaboration on NIH Roadmap Initiative
News Mar 28, 2006
PerkinElmer Inc. has announced that it has entered a collaborative agreement with the National Institute of Health's National Chemical Genomics Center (NCGC) to provide reagents, instrumentation and scientific support for identifying small molecules.
As part of the collaboration, NCGC gains access to PerkinElmer's extensive reagent portfolio and scientific experts who are helping develop assays and protocols.
The three leading reagent technologies being used are AlphaScreen™, LANCE™ and DELFIA™.
AlphaScreen is a sensitive non-radioactive homogeneous bead-based technology that is designed to allow the screening of a wide range of biological interactions, particularly with the largest target class - kinases.
LANCE is a homogeneous technology that supports the measurement of various analytes and screens diverse biological interactions.
DELFIA, the heterogeneous counterpart to LANCE, is a fluorescence technology allowing for sensitive and multiplexed detection of analytes.
"We are very pleased to be partnering with NCGC to help accelerate their chemical genomics efforts," said Robert F. Friel, president, PerkinElmer Life and Analytical Sciences.
"We believe that our capability to provide comprehensive solutions helps eliminate the time consuming and expensive problem of trying to unify all the components of drug discovery - liquid handling and prep, assay development and multilabel detection."
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Targeting a Leaky Protein that Causes ParalysisNews
A rare genetic disorder in which people are overcome suddenly with profound muscle weakness is caused by a hole in a membrane protein that allows sodium ions to leak across cell membranes. Compounds containing a chemical group called guanidinium can block the pore created by the mutation and stop the sodium leak without altering the voltage sensor’s ability to function.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018